LIFR, Recombinant, Mouse

Swiss Prot

P42703

Grade

Highly Purified

Shipping Temp

Blue Ice

Storage Temp

-20°C

Leukemia Inhibitory Factor Receptor alpha (LIF R-alpha), also known as LIFR beta and CD118, is a 190kD type I transmembrane protein in the Interleukin-6 receptor family. Members of this family mediate the biological effects of Cardiotrophin-1, CLC, CNTF, IL-6, IL-11, IL-27, and Oncostatin M. Mature mouse LIF R-alpha consists of a 785aa extracellular domain (ECD) with two cytokine receptor homology domains, one WSxWS motif, and three fibronectin type III repeats, followed by a 25aa transmembrane segment and a 239aa cytoplasmic domain. Within the ECD, mouse LIF R-alpha shares 73% and 90% aa sequence identity with human and rat LIF R-alpha, respectively. Alternative splicing generates a 90kD soluble form of the mouse LIF R-alpha ECD. LIF R-alpha binds the pleiotropic cytokine LIF with low affinity, and the soluble isoform retains LIF-binding activity. Binding affinity is increased by the ligand-induced association of LIF R-alpha with the signal transducing subunit gp130. The LIF R-alpha/gp130 receptor complex also transduces Oncostatin M signals, although LIF R-alpha alone does not interact with Oncostatin M. gp130 associates with different ligand-specific receptors to form signaling receptor complexes for the other IL-6 family ligands. The CNTF receptor is a ternary complex that contains CNTF R-alpha and gp130 as well as LIF R-alpha. LIF R-alpha is widely expressed, and LIF induces the proliferation, differentiation, and activation of cells in many tissues. In particular, LIF R-alpha plays an important role in several aspects of early pregnancy such as blastocyst implantation in the uterus.

NS0-derived recombinant protein corresponding to Leu44-Ser828, from human LIFR alpha, fused with a C-terminal 6-His tag. Swiss/Uniprot: P42703

Molecular Mass

Predicted: 89.4kD Observed: 125-140kD by SDS-PAGE (reducing conditions)

N-terminal Sequence Analysis

Leu44

Activity

Measured by its ability to inhibit LIF-dependent proliferation of TF-1 human erythroleukemic cells. The ED50 for this effect is typically 0.8-4ug/ml.

Storage and Stability

Lyophilized and reconstituted products are stable for 6 months after receipt at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Source

Recombinant, NS0 cells

Purity

~95% (SDS-PAGE, reducing conditions)

Form

Supplied as a lyophilized powder from PBS. Reconstitute to 0.5mg/ml with sterile PBS.

Important Note

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

Form

Supplied as a lyophilized powder from PBS. Reconstitute with 100ul sterile PBS.

Purity

~95% (SDS-PAGE, reducing conditions). Endotoxin: ≤0.01EU/ug (LAL).

References

1. MullerNewen, G. (2003) Science STKE 2003:pe40. 2. Gearing, D.P. et al. (1991) EMBO J. 10:2839. 3. Tomida, M. et al. (1994) J. Biochem. 115:557. 4. Owczarek, C.M. et al. (1996) J. Biol. Chem. 271:5495. 5. Layton, M.J. et al. (1992) Proc. Natl. Acad. Sci. 89:8616. 6. Gearing, D.P. et al. (1992) Science 255:1434. 7. Giese, B. et al. (2005) J. Cell Sci. 118:5129. 8. Ip, N.Y. et al. (1992) Cell 69:1121. 9. Davis, S. et al. (1993) Science 260:1805. 10. Metcalf, D (2003) Stem Cells 21:5. 11. Kubota, Y. et al. (2008) J. Clin. Invest. 118:2393. 12. Paiva, P. et al. (2009) Cytokine Growth Factor Rev. 20:319. 13. Stewart, C.L. et al. (1992) Nature 359:76. 14. Cheng, J.G. et al. (2001) Proc. Natl. Acad. Sci. 98:8680.